What is Wedbush’s Estimate for FENC Q1 Earnings?

Fennec Pharmaceuticals Inc (NASDAQ:FENC) – Wedbush issued their Q1 2026 earnings per share (EPS) estimates for Fennec Pharmaceuticals in a research note issued on Tuesday, May 13th. Wedbush analyst D. Nierengarten anticipates that the company will earn $0.15 per share for the quarter. Wedbush has a “Outperform” rating and a $13.00 price objective on the stock. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is ($0.11) per share. Wedbush also issued estimates for Fennec Pharmaceuticals’ Q2 2026 earnings at $0.23 EPS, Q3 2026 earnings at $0.30 EPS, Q4 2026 earnings at $0.36 EPS and FY2028 earnings at $2.29 EPS.

Several other analysts have also commented on the company. HC Wainwright reiterated a “buy” rating and set a $13.00 price objective on shares of Fennec Pharmaceuticals in a report on Tuesday, March 11th. Craig Hallum raised their target price on Fennec Pharmaceuticals from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday.

Fennec Pharmaceuticals Trading Up 4.4%

Shares of FENC opened at $6.84 on Thursday. Fennec Pharmaceuticals has a 12 month low of $3.96 and a 12 month high of $7.64. The stock has a fifty day moving average price of $5.91 and a 200-day moving average price of $5.93. The firm has a market cap of $188.74 million, a PE ratio of -68.39 and a beta of 0.32.

Fennec Pharmaceuticals (NASDAQ:FENC) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.08. Fennec Pharmaceuticals had a negative return on equity of 53.38% and a negative net margin of 2.30%. The firm had revenue of $8.51 million during the quarter, compared to analyst estimates of $8.18 million. During the same quarter in the prior year, the business posted $0.41 EPS.

Insider Buying and Selling

In related news, Director Rosty Raykov sold 10,000 shares of the firm’s stock in a transaction dated Friday, April 4th. The shares were sold at an average price of $5.25, for a total value of $52,500.00. Following the transaction, the director now directly owns 61,156 shares of the company’s stock, valued at approximately $321,069. This trade represents a 14.05% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold 30,000 shares of company stock worth $183,500 in the last 90 days. Insiders own 11.76% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC purchased a new position in Fennec Pharmaceuticals in the 1st quarter valued at about $66,000. Intech Investment Management LLC purchased a new position in Fennec Pharmaceuticals in the 4th quarter valued at about $69,000. Wells Fargo & Company MN lifted its stake in Fennec Pharmaceuticals by 31.6% in the 4th quarter. Wells Fargo & Company MN now owns 13,152 shares of the company’s stock valued at $83,000 after buying an additional 3,155 shares in the last quarter. Pinnacle Wealth Planning Services Inc. purchased a new position in Fennec Pharmaceuticals in the 4th quarter valued at about $97,000. Finally, MetLife Investment Management LLC purchased a new position in Fennec Pharmaceuticals in the 4th quarter valued at about $99,000. 55.51% of the stock is owned by hedge funds and other institutional investors.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.